Active substanceImipenem + CilastatinImipenem + Cilastatin
Similar drugsTo uncover
  • Aquapenem
    powder in / in 
  • Grimipenem®
    powder d / infusion 
    PREBAND PFC, LLC     Russia
  • Imipenem + cilastatin
    powder in / in 
    KRASFARMA, JSC     Russia
  • Imipenem and Cilastatin Jodas
    powder d / infusion 
  • Imipenem and Cilastatin Spencer
    powder d / infusion 
    Spencer Pharma UK Limited     United Kingdom
  • Imipenem + Cilastatin
    powder d / infusion 
    HIMFARM, JSC     Kazakhstan
  • Imipenem + Cilastatin
    powder d / infusion 
    VELFARM, LLC     Republic of San Marino
  • Imipenem + Cilastatin-Vial
    powder d / infusion 
    VIAL, LLC     Russia
  • Imipenem / Cilastatin Kabi
    powder d / infusion 
  • Tienam®
    powder d / infusion 
    Merck Sharp and Doum B.V.     Netherlands
  • Tiepenem
    powder in / in 
       
  • Cilapenem
    powder in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Cilapenem
    powder d / infusion 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Cilaspin
    powder d / infusion 
  • Dosage form: & nbspPowder for solution for infusion
    Composition:

    1 bottle contains:

    active substance: sterile imipenem (equivalent to anhydrous tienamycin forms and monohydrate) 500 mg, sterile cilastatin sodium (equivalent to anhydrous acid) 500 mg;

    Excipients: sterile sodium bicarbonate (equivalent to anhydrous component) 20 mg.

    Description:

    Powder from white to light yellow color.

    Pharmacotherapeutic group:antibiotic-carbapenem + dehydropeptidase inhibitor
    ATX: & nbsp

    J.01.D.H.51   Imipenem and dehydropeptidase inhibitor

    Pharmacodynamics:

    Tienam® consists of two components:

    1) imipenem, the first representative of a new class of beta-lactam antibiotics - tienamycins;

    2) cilastatin sodium - a specific enzyme inhibitor that inhibits the metabolism of imipenem in the kidneys and significantly increases the concentration of unchanged imipenem in the urinary tract.

    Imipenem is a highly effective inhibitor of bacterial cell wall synthesis and has a bactericidal action against a wide range of pathogenic microorganisms gram-positive and gram-negative, both aerobic and anaerobic.

    The stability of the Tienam® preparation to cleavage with bacterial beta-lactamases provides its effectiveness against many microorganisms, such as Pseudomonas aeruginosa, Serratia spp. and Enterobacter spp., resistant to the action of most beta-lactam antibiotics.

    Cilastatin does not have its own antibacterial activity and does not inhibit beta-lactamase bacteria.

    The antibacterial spectrum of Tienam® encompasses virtually all clinically relevant pathogens. Spectrum of antimicrobial susceptibility imipenem in vivo and in vitro:

    Aerobic Gram-positive microorganisms:

    Enterococcus faecalis (Enterococcus faecium not sensitive in vitro)

    Staphylococcus aureus, including penicillinase-forming strains

    Staphylococcus epidermidis, including penicillinase-forming strains (methicillin-resistant staphylococci are insensitive to imipenem)

    Streptococcus agalactiae (Group B Streptococcus)

    Streptococcus pneumoniae

    Streptococcus pyogenes

    Aerobic Gram-negative microorganisms:

    Acinetobacter spp.

    Citrobacter spp.

    Enterobacter spp.

    Escherichia coli

    Gardnerella vaginalis

    Haemophilus influenzae

    Haemophilus parainfluenzae

    Klebsiella spp.

    Morganella morganii

    Proteus vulgaris

    Providencia rettgeri

    Pseudomonas aeruginosa (imipenem is inactive in vitro against Stenotrophomonas [previously Xanthomonas, before Pseudomonas] maltophilia and some strains Burkholderia cepacia)

    Serratia spp., including S. marcescens

    Aerobic Gram-positive microorganisms:

    Bifidobacterium spp.

    Clostridium spp.

    Eubacterium spp.

    Peptococcus spp.

    Peptostreptococcus spp.

    Propionibacterium spp.

    Anaerobic Gram-negative microorganisms:

    Bacteroides spp., including B.fragilis

    Fusobacterium spp.

    Sensitive in vitro (clinical efficacy not established):

    Aerobic Gram-positive microorganisms:

    Youillus spp.

    Listeria monocytogenes

    Nocardia spp.

    Staphylococcus saprophyticus

    Streptococcus spp. groups C, G and Viridans

    Aerobic Gram-negative microorganisms:

    Aeromonas hydrophila

    Alcaligenes spp.

    Capnocytophaga spp.

    Haemophilus ducreyi

    Neisseria gonorrhoeae, including penicillinase-forming strains Pasteurella spp.

    Providencia stuartii

    Anaerobic Gram-negative microorganisms:

    Prevotella bivia

    Prevotella disiens

    Prevotella melaninogenica

    Veillonella spp.

    In vitro acts synergistically with aminoglycosides against certain strains Pseudomonas aeruginosa.

    Pharmacokinetics:

    After iv injection of the drug Tienam®, the time to reach the maximum concentration (TCmOh) in the plasma is 20 minutes for both components. The maximum concentration (CmOh) reaches values ​​of 21 to 58 μg / ml for imipenem and 21 to 55 μg / ml for cilastatin. After the administration of Tienam® for 4-6 hours CmOh Imipenem decreases to a value of 1 μg / ml and lower.

    The half-life for each component is 1 hour. Binding to plasma proteins is 20% for imipenem and 40% for cilastatin. About 70% injected into / in imipenem is excreted by the kidneys within 10 hours. The concentration of imipenem in urine above 10 μg / ml can persist for 8 hours after intravenous administration of Tienam®. About 70-80% of cilastatin is excreted by the kidneys within 10 hours after intravenous administration of the drug.

    With intravenous administration of Tienam® every 6 hours, patients with normal renal function did not observe imipenem / cilastatin cumulation in plasma or urine. After intravenous administration of Tienam® in a dose of 1 g, the following mean values ​​of the concentration of imipenem in tissues and media of the human body were determined:

    Fabric or medium

    The concentration of imipenem is μg / ml or μg / g

    Measurement time (h)

    Vitreous body of the eyeball

    3,4

    3,5

    Intraocular fluid

    2,99

    2,0

    Lung tissue

    5,6

    1,0

    Sputum

    2,1

    1,0

    Pleural fluid

    22,0

    1,0

    Peritoneal fluid

    23,9

    2,0

    Bile

    5,3

    2,25

    Liquor (without inflammation)

    1,0

    4,0

    Liqvor (with inflammation)

    2,6

    2,0

    The secret of the prostate

    0,2

    1,0-1,5

    Prostate tissue

    5,3

    1,0-2,75

    Fallopian tubes

    13,6

    1,0

    Endometrium

    11,0

    1,0

    Myometrium

    5,0

    1,0

    Bone

    2,6

    1,0

    Interstitial fluid

    16,4

    1,0

    Leather

    4,4

    1,0

    Connective tissue

    4,4

    1,0

    Indications:

    Tienam® for intravenous administration is used in the treatment of severe infections caused by sensitive microorganisms, as well as for empirical therapy of the infectious process even before the determination of its bacterial pathogens. The drug Tienam® for IV administration is indicated for treatment of:

    - infections of the lower respiratory tract caused by Streptococcus pneumoniae, Staphylococcus aureus (penicillinase-producing strains), Acinetobacter spp., Enterobacter spp., Escherichia coli, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella spp., Serratia marcescens;

    - urinary tract infections (complicated and uncomplicated) caused by Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter spp., Escherichia coli, Klebsiella spp., Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa;

    - intra-abdominal infections caused by Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Citrobacter spp., Enterobacter spp., Escherichia coli, Klebsiella spp, Morganella morganii, Proteus spp., Pseudomonas aeruginosa, Bifidobacterium spp., Clostridium spp., Eubacterium spp., Peptococcus spp., Peptostreptococcus spp., Propionibacterium spp., Bacteroides spp., including B.fragilis, Fusobacterium spp.;

    - gynecological infections caused by Enterococcus faecalis; Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Escherichia coli; Streptococcus agalactiae (group streptococci B), Enterobacter spp., Escherichia coli, Gardnerella vaginalis, Klebsiella spp., Proteus spp., Bifidobacterium spp., Peptococcus spp., Peptostreptococcus spp., Propionibacterium spp., Bacteroides spp., including B.fragilis;

    - bacterial septicemia caused by Streptococcus pneumoniae, Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Enterobacter spp., Escherichia coli, Klebsiella spp, Serratia spp., Bacteroides spp., including B.fragilis, Pseudomonas aeruginosa;

    - infections of bones and joints caused by Enterococcus faecalis; Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Enterobacter spp., Pseudomonas aeruginosa;

    - infections of the skin and soft tissues caused by Streptococcus pyogenes, Enterococcus faecalis, Staphylococcus aureus (penicillinase-producing strains), Staphylococcus epidermidis, Acinetobacter spp., Citrobacter spp., Enterobacter spp., Escherichia coli, Klebsiella spp, Morganella morganii, Proteus vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, Serratia spp., Peptococcus spp., Peptostreptococcus spp., Bacteroides spp., including B. fragilis, Fusobacterium spp.;

    - infectious endocarditis caused by Staphylococcus aureus (penicillinase-producing strains).

    To prevent postoperative infections in patients at risk with a high probability of postoperative infectious complications, as well as in patients with a high risk of intraoperative infection during surgical intervention.

    Contraindications:

    - Hypersensitivity to any of the components of the drug, other beta-lactam antibiotics, penicillins and cephalosporins;

    - children up to 3 months;

    - children with impaired renal function (serum creatinine> 2 mg / dL);

    - patients with creatinine clearance less than 5 ml / min / 1.73 m2.

    Carefully:

    - Pseudomembranous colitis;

    - patients who have a history of gastrointestinal disease;

    - patients with creatinine clearance <70 ml / min / 1.73 m2;

    - patients on hemodialysis;

    - patients with CNS diseases.

    Pregnancy and lactation:

    Studies in pregnant women have not been conducted. The drug Tienam® should be used during pregnancy only if the benefit of the treatment justifies the potential risk to the fetus.

    Imipenem is found in human breast milk.If the use of Tienam® is recognized as necessary, then breastfeeding of the baby should be discontinued.

    Dosing and Administration:

    DOSAGE FORM FOR INTRAVENOUS APPLICATION SHOULD NOT BE INTRODUCED INSIDE.

    The recommendations for the dosage of Tienam® indicated the amount of imipenem to be administered.

    The calculation of the total daily dose of Tienam® should be based on the severity of the infection and be divided into several applications at equal doses, taking into account the sensitivity of one or more pathogenic microorganisms, renal function and body weight.

    Dosage regimen for adult patients with normal renal function

    The dosages given in Table 1 are calculated for patients with normal renal function (creatinine clearance greater than 70 ml / min / 1.73 m2) and body weight ≥ 70 kg. In patients with creatinine clearance ≤ 70 ml / mii / 1.73 m2 (see Table 2) and / or a body weight of less than 70 kg (see Table 3), a reduction in the dose of the drug is necessary. It is especially important to reduce the dose depending on body weight in those patients whose weight is well below 70 kg and / or there is moderate or severe renal failure.

    The average therapeutic daily dose is 1-2 g imipenem, divided into 3-4 applications (see Table 1). For treatment of moderate infections, the drug can also be applied at a dose of 1 g twice daily.

    In the case of infections caused by less sensitive microorganisms, the daily dose of the drug for intravenous infusions can be increased to a maximum of 4 g (imipenem) per day or 50 mg / kg per day, whichever dose is lower. Each dose of Tienam® for intravenous infusion, less than or equal to 500 mg, should be administered intravenously for 20-30 minutes. Each dose of more than 500 mg should be administered intravenously for 40-60 minutes. Patients who experience nausea during infusion should slow the rate of injection.

    Table 1. Dosing regimen of Tienam® for intravenous infusion to adult patients with normal renal function and body weight ≥70 kg*

    Severity of infection

    Dose

    imipenem, mg

    Break between infusions

    Total daily dose

    easy

    250 mg

    6 hours

    1.0 g

    mean

    500 mg

    8 ocloc'k

    1.5 g

    1000 mg

    12 hours

    2.0 g

    Heavy

    (sensitive pathogens)

    500 mg

    6 hours

    2.0 g

    heavy and / or

    threatening to life,

    caused by less sensitive microorganisms (primarily some strains of P. aeruginosa)

    1000 mg

    8 ocloc'k

    3.0 g

    1000 mg

    6 hours

    4.0 g

    *In patients with a body weight of less than 70 kg, a further proportional reduction in the dose to be administered is necessary.

    Due to the high antimicrobial activity of Tienam®, it is recommended that its total daily dose not exceed 50 mg / kg or 4 g (imipenem) / day, whichever dose is lower. Although patients with cystic fibrosis with normal renal function were treated with Tienam® at a dose of up to 90 mg / kg per day, divided into several applications, the total dose did not exceed 4 g (imipenem) per day. The drug Tienam ® was successfully used in monotherapy in cancer patients with weakened immunity in the case of confirmed or suspected infections, for example, sepsis.

    Dosing schedule for adult patients with impaired renal function

    To correct the dose of the drug in the treatment of adult patients with impaired renal function, it is necessary:

    - Based on the characteristics of the infection, choose from Table 1 the total daily dose of the drug;

    - from Table 2, select the appropriate reduced dose of the drug, based on the daily dose (Table 1) and the creatinine clearance of the patient (to calculate the infusion time,section "Dosage regimen for adult patients with normal renal function");

    - from Table 3, choose in the left column the body weight nearest to the patient's body weight (kg).

    Table 2. Dosing regimen of Tienam® for intravenous infusions for adult patients with impaired renal function and body weight≥70 kg*

    Total daily dose

    Clearance creatinine (ml / min / 1.73 m2)

    from Table 1

    41-70

    21-40

    6-20

    1.0 g per day

    250 mg every 8 hours

    250 mg in 12 hours

    250 mg in 12 hours

    1.5 g per day

    250 mg in 6 hours

    250 mg every 8 hours

    250 mg in 12 hours

    2.0 g per day

    500 mg in 8 hours

    250 mg in 6 hours

    250 mg in 12 hours

    3.0 g per day

    500 mg in 6 hours

    500 mg in 8 hours

    500 mg in 12 hours

    4.0 grams per day

    750 mg in 8 hours

    500 mg in 6 hours

    500 mg in 12 hours

    * Patients with a body weight of less than 70 kg need a further proportional reduction in doses administered.

    Table 3. Dosing regimen of Tienam® preparation for the duration of intravenous infusion to adult patients with impaired renal function and / or body weight less than 70 kg

    The maximum daily dose of 1.0 g

    Body weight (kg)

    Creatinine clearance (ml / min / 1.73 m2)

    ≥71

    41-70

    21-40

    6-20

    ≥70

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    250 mg each

    in 12 hours

    60

    250 mg each

    after 8 hours

    125 mg

    in 6 hours

    250 mg each

    in 12 hours

    125 mg

    in 12 hours

    50

    125 mg

    in 6 hours

    125 mg

    in 6 hours

    125 mg

    after 8 hours

    125 mg

    in 12 hours

    40

    125 mg

    in 6 hours

    125 mg

    after 8 hours

    125 mg

    in 12 hours

    125 mg

    in 12 hours

    30

    125 mg

    after 8 hours

    125 mg

    after 8 hours

    125 mg

    in 12 hours

    125 mg

    in 12 hours

    The maximum daily dose of 1.5 g

    Weight

    Creatinine clearance (ml / min / 1.73 m2)

    body weight (kg)

    ≥71

    41-70

    21-40

    6-20

    ≥70

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    60

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    50

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    250 mg each

    in 12 hours

    40

    250 mg each

    after 8 hours

    125 mg

    in 6 hours

    125 mg

    after 8 hours

    125 mg

    in 12 hours

    30

    125 mg

    in 6 hours

    125 mg

    after 8 hours

    125 mg

    after 8 hours

    125 mg

    in 12 hours

    The maximum daily dose of 2.0 g

    Weight

    Tate (kg)

    Creatinine clearance (ml / min / 1,73 m2)

    ≥71

    41-70

    21-40

    6-20

    ≥70

    500 mg each

    in 6 hours

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    in 12 hours

    60

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    50

    250 mg each

    in 6 hours

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    40

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    250 mg each

    in 12 hours

    30

    250 mg each

    after 8 hours

    125 mg

    in 6 hours

    125 mg

    after 8 hours

    125 mg

    in 12 hours

    The maximum daily dose of 3.0 g

    Weight

    Tate (kg)

    Creatinine clearance (ml / min / 1.73 m2)

    ≥71

    41-70

    21-40

    6-20

    ≥70

    1000 mg

    after 8 hours

    500 mg each

    in 6 hours

    500 mg each

    after 8 hours

    500 mg each

    in 12 hours

    50

    750 mg

    after 8 hours

    500 mg each

    after 8 hours

    500 mg each

    after 8 hours

    500 mg each

    in 12 hours

    50

    500 mg each

    in 6 hours

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    in 12 hours

    40

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    30

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    The maximum daily dose of 4.0 g

    Body weight (kg)

    Creatinine clearance (ml / min / 1.73 m2)

    ≥71

    41-70

    21-40

    6-20

    ≥70

    1000 mg

    in 6 hours

    750 mg

    after 8 hours

    500 mg each

    in 6 hours

    500 mg each

    in 12 hours

    60

    1000 mg

    after 8 hours

    750 mg

    after 8 hours

    500 mg each

    after 8 hours

    500 mg each

    in 12 hours

    50

    750 mg

    after 8 hours

    500 mg each

    in 6 hours

    500 mg each

    after 8 hours

    500 mg each

    in 12 hours

    40

    500 mg each

    in 6 hours

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    in 12 hours

    50

    500 mg each

    after 8 hours

    250 mg each

    in 6 hours

    250 mg each

    after 8 hours

    250 mg each

    in 12 hours

    When a dose of 500 mg is administered to patients with a creatinine clearance of 6-20 ml / min / 1.73 m2 may increase the risk of seizures.

    The drug Tienam® should not be administered intravenously to patients with creatinine clearance less than 5 ml / min / 1.73 m2 With the exception of cases where hemodialysis will be performed no later than 48 hours after the infusion of Tienam®.

    Hemodialysis

    When treating patients with creatinine clearance less than 5 ml / min / 1.73 m2, on hemodialysis, recommendations should be applied but the dosage regimen of Tienam® for patients with creatinine clearance 6-20 ml / min / 1.73 m2 (see the section "Treatment: Dosage Scheme for Adult Patients with Impaired Renal Function").

    Both imipenem and cilastatin are excreted during hemodialysis from the circulatory system. In this regard, the drug Tienam® for intravenous infusions should be administered to patients after hemodialysis and then at 12-hour intervals from the end of the procedure. Patients on hemodialysis, especially if they have central nervous system diseases, should be carefully monitored; the administration of Tienam® to patients undergoing hemodialysis is recommended only when the benefits of treatment exceed the potential risk of seizures (see Table 1).see "With caution").

    At present, there is insufficient data to recommend the drug Tienam® for intravenous administration to patients on peritoneal dialysis.

    The state of the kidney in elderly patients can not be fully determined only on the basis of measuring the level of residual blood nitrogen or creatinine. To determine the dosage of such patients, it is recommended to determine the clearance of creatinine.

    Elderly patients

    For elderly patients with normal renal function, dose adjustment is not required.

    Impaired liver function

    For patients with impaired liver function, dose adjustment is not required.

    Prevention: dosing regimen for adult patients

    To prevent postoperative infections in adults, the Tienam® preparation for intravenous infusions should be administered at a dose of 1 g for anesthesia and then 1 g after 3 hoursa. In the case of surgical intervention with a high degree of risk (for example, in operations on the thick and rectum), two additional doses of 500 mg should be administered at 8 and 16 hours after the initial anesthesia.

    Dosage regimen for children from 3 months of age

    The following dosing regimen is recommended for children:

    - Children with a body weight of ≥40 kg should receive the same doses as adult patients.

    - Children older than 3 months with a body weight of less than 40 kg should receive the drug at a dose of 15 mg / kg at 6-hour intervals. The maximum daily dose should not exceed 2 g.

    The drug Tienam® is not recommended for the treatment of meningitis. If suspected of having meningitis, appropriate antibiotics should be prescribed.

    Preparation of a solution for intravenous infusion

    The drug Tienam® for intravenous infusion should not be mixed or added to other antibiotics.

    The drug form of Tienam® for intravenous infusions is chemically incompatible with lactic acid (lactate) and should not be prepared on the basis of solvents containing lactate. However, intravenously, the Tienam® preparation can be administered via the same infusion system as the lactate-containing solution.

    A solution of the preparation Tienam® for intravenous infusions is prepared in accordance with the following Table 4. The final infusion solution must be shaken until a clear solution is obtained.The color of the solutions of the preparation Tienam® varies from colorless to yellow (a change in color within these limits does not affect the activity of the drug).

    Table 4. Preparation of Tienam® Solution for Intravenous Infusions

    The dose of Tienam® for intravenous infusions (mg imipenem)

    Volume of solvent added (ml)

    The average concept of the infusion solution of Tienam® (mg / ml imipenem)

    500

    100

    5

    For a bottle of 20 ml

    The vial Tienam® previously necessary to add 10 ml of the solvent from the list presented in Table 5. The obtained primary slurry must be thoroughly shake and add an infusion bottle containing 90 ml of solvent infusion.

    PRIMARY SUSPENSION CAN NOT BE USED FOR INTRODUCTION.

    For the complete transfer of the drug, the procedure must be repeated by adding 10 ml of the previously obtained solution from the infusion bottle to the vial of powder residues. The resulting suspension should be thoroughly shaken and added to an infusion bottle containing 90 ml of an infusion solvent.

    The total volume of the solvent is 100 ml.

    The final infusion solution must be shaken until a clear solution is obtained.

    Table 5 shows the timing of the use of the infusion solution of Tienam®, prepared from a number of infusion solvents and stored at room temperature or in a refrigerator.

    Table 5.

    Solvent

    The period of stability n

    rhyarate

    Room temperature (25 ° C)

    Refrigerator (4 ° C)

    0.9% solution of sodium chloride

    4 hours

    24 hours

    5% dextrose solution

    4 hours

    24 hours

    10% dextrose solution

    4 hours

    24 hours

    5% dextrose solution and 0.9% sodium chloride solution

    4 hours

    24 hours

    5% dextrose solution and 0.45% sodium chloride solution

    4 hours

    24 hours

    5% dextrose solution and 0.225% sodium chloride solution

    4 hours

    24 hours

    5% dextrose solution and 0.15%

    potassium chloride solution

    4 hours

    24 hours

    5% and 10% mannitol solution

    4 hours

    24 hours

    Side effects:

    In clinical studies imipenem / cilastatin was intravenously administered to 1723 patients. The most frequent systemic side effects probably associated with the use of the drug were nausea (2.0%), diarrhea (1.8%), vomiting (1.5%), rash (0.9%), fever (0.5 %), lowering blood pressure (0.4%), convulsions (0.4%) (see "Special instructions"), dizziness (0.3%), pruritus (0.3%), urticaria (0, 2%), drowsiness (0.2%). The most frequent local side effects were phlebitis / thrombophlebitis (3.1%), pain at the injection site (0.7%), erythema at the site of injection (0.4%) and vein scarring (0.2%).It has also often been reported that the activity of serum transaminases and alkaline phosphatase increases.

    The side effects listed in clinical trials and post-registration experience are listed below.

    Registered side effects are classified by frequency: very frequent (≥1/10), frequent (≥1 / 100, <1/10), infrequent (≥1 / 1000, <1/100), rare (≥1 / 10000, < 1/1000), very rare (<1/10000), the frequency is unknown.

    Infectious and parasitic diseases

    Rare: pseudomembranous colitis, candidiasis.

    Very rare: gastroenteritis.

    On the part of the blood and lymphatic system

    Frequent: eosinophilia.

    Infrequent: pancytopenia, neutropenia, leukopenia, thrombocytopenia, thrombocytosis.

    Rare: agranulocytosis.

    Very rare: hemolytic anemia, oppression of red bone marrow function.

    From the immune system

    Rare: anaphylactic reactions.

    From the side of the psyche

    Infrequent: mental disorders, including hallucinations and confusions.

    From the nervous system

    Infrequent: convulsions, myoclonia, dizziness, drowsiness.

    Rare: encephalopathy, paresthesia, tremor, perversion of taste.

    Very rare: exacerbation of myasthenia gravis, headache.

    Frequency unknown: agitation, dyskinesia.

    From the side of the hearing organ and labyrinthine disorders

    Rare: hearing loss.

    Very rare: twirls, ringing in the ears.

    From the heart

    Very rare: cyanosis, tachycardia, palpitation.

    From the side of the vessels

    Frequent: thrombophlebitis.

    Infrequent: lowering of blood pressure.

    Very rare: "tides".

    On the part of the respiratory system, the organs of the thorax and the mediastinum

    Very rare: shortness of breath, hyperventilation, sore throat.

    From the gastrointestinal tract

    Frequent: diarrhea, vomiting, nausea. Nausea and / or vomiting with Tienam® was more common in patients with granulocytopenia.

    Rare: staining of teeth and / or tongue.

    Very rare: hemorrhagic colitis, abdominal pain, heartburn, glossitis, hypertrophy of the papillae of the tongue, hypersalivation.

    From the liver and biliary tract

    Rare: hepatic insufficiency, hepatitis.

    Very rare: fulminant hepatitis.

    From the skin and subcutaneous tissues

    Frequent: rash (including exanthematous).

    Infrequent: hives, itching.

    Rare: toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis.

    Very rare: hyperhidrosis, changes in the structure of the skin.

    From the musculoskeletal and connective tissue

    Very rare: polyarthralgia, pain in the thoracic spine.

    From the side of the kidneys and urinary tract

    Rare: acute renal failure, oliguria / anuria, polyuria, change in color of urine (it is safe and should not be mistaken for hematuria). The role of Tienam® in changes in renal function is difficult to assess, since there are usually other factors predisposing to prerenal azotemia or impaired renal function.

    From the genitals and breast

    Very rare: genital itching.

    Common disorders and disorders together

    Infrequent: fever, pain and compaction at the site of administration of the drug, erythema at the injection site.

    Very rare: a feeling of discomfort in the chest, asthenia / weakness.

    Laboratory indicators

    Frequent: increased activity of serum transaminases, increased activity of alkaline phosphatase.

    Infrequent: positive Coombs direct test, increased prothrombin time, decreased hemoglobin, increased serum bilirubin concentration, increased serum creatinine concentration, increased blood urea nitrogen concentration.

    Children (over 3 months)

    In a clinical study involving 178 children older than 3 months, the observed side effects were comparable to the side effects recorded in adult patients.

    Overdose:

    Overdose Symptoms correspond to the profile of adverse reactions and can include convulsions, confusion, tremor, nausea, vomiting, lowering blood pressure, bradycardia.

    Special information on treatment there is no overdose of Tienam®. Imipenem-cilastatin sodium is excreted during hemodialysis, however, the effectiveness of this procedure with an overdose of the drug is unknown.

    Interaction:

    In patients taking both ganciclovir and Tienam® preparation, generalized seizures were observed. These drugs can not be administered concomitantly, except when the potential benefits exceed the possible risk.

    Simultaneous application with probenecid is accompanied by a minimal increase in plasma concentration and half-life of imipenem, and therefore the simultaneous use of probenecid and Tienam® is not recommended.

    Clinical cases described in the literature show that the simultaneous use of carbapenems, including imipenem, with valproic acid or sodium divalproate leads to a decrease in the concentration of valproic acid. As a result of this interaction, the concentration of valproic acid may fall below the therapeutic level, which increases the risk of developing seizures. Although the mechanism of interaction is unknown, the data in vitro and animal studies suggest that carbapenems may inhibit hydrolysis, as a result of which the glucuronide metabolite of valproic acid (VPA-g) is converted back to valproic acid, which leads to a decrease in the concentration of valproic acid in the blood plasma (see section "Special instructions").

    Oral anticoagulants. The simultaneous use of antibiotics with warfarin can enhance its anticoagulant effect.There are numerous reports of increased anticoagulant effect of orally administered anticoagulants, including warfarin, in patients who simultaneously take antibacterial drugs. The risk may vary depending on the infectious agent, the age and general condition of the patient, so it is difficult to assess the effect of antibiotics on the increase in INR (the international normalized ratio). It is recommended to periodically monitor the value of INR during and immediately after the simultaneous use of antibiotics with oral anticoagulants.

    The drug Tienam® should not be confused with other antibiotics, while simultaneous isolated administration with other antibiotics (eg, aminoglycosides) is permitted.

    Special instructions:

    The intravenous route of administration of Tienam® is preferably used in the initial stages of treatment of bacterial sepsis, endocarditis and other severe or life-threatening infections, including lower respiratory tract infections caused by Pseudomonas aeruginosa, and in the case of significant physiological disorders, for example, shock.

    The drug Tienam® contains 37.5 mg of sodium (1.6 meq).

    As in the case of other beta-lactam antibiotics, Pseudomonas aeruginosa can quickly develop resistance to the drug Tienam® during the treatment. Therefore, during the treatment of infections caused by Pseudomonas aeruginosa, it is recommended to conduct periodic tests for sensitivity to the antibiotic according to the clinical situation.

    In order to prevent the development of resistance and maintain the effectiveness of the drug Tienam® in clinical practice, the drug should be used only for the treatment of infections caused by proven (or presumably) susceptible to imipenem microorganisms. In the presence of information on the identified pathogen and its sensitivity to antibiotics, the physician is guided by it to choose the optimal antibiotic, and in the absence of such an empirical choice of an antibacterial drug is carried out on the basis of regional epidemiological data and sensitivity data.

    There is evidence of partial cross-allergy when using Tienam® and other beta-lactam antibiotics-penicillins and cephalosporins.For most antibiotics of the beta-lactam group, the possibility of developing severe reactions (including anaphylaxis) has been reported. Before starting treatment with Tienam®, the patient should be thoroughly questioned about previous hypersensitivity reactions to beta-lactam antibiotics. If there is an allergic reaction to Tienam®, it should be discarded and appropriate measures taken.

    Clinical cases described in the literature show that the simultaneous use of carbapenems, including imipenem, with valproic acid or sodium divalproate, leads to a decrease in the concentration of valproic acid. As a result of this interaction, the concentration of valproic acid may fall below the therapeutic level, which increases the risk of developing seizures. An increase in the dose of valproic acid or sodium divalproate may not be sufficient to overcome the effects of the interaction. Simultaneous use of imipenem and valproic acid / sodium divalproex is not recommended. Consider the possibility of treating infections with antibiotics from other groups (not carbapenems) in patients receiving anticonvulsant therapy with valproic acid or sodium divalpro proteate.If it is necessary to use Tienam®, additional anticonvulsant therapy may be required (see section "Interaction with Other Drugs").

    With the use of almost all antibacterial drugs, it is possible to develop pseudomembranous colitis, which in severity can range from mild to life-threatening. In this regard, patients who have a history of gastrointestinal disease, especially colitis, antibiotics should be administered with caution. It is important to consider the possibility of such a diagnosis, as pseudomembranous colitis, in patients coming with diarrhea after using antibacterial drugs. Although studies show that the main cause of "antibiotic-related colitis" is the toxin produced Clostridium difficile, Other possible causes should be taken into account. Do not use drugs that inhibit the intestinal motility.

    Liver function

    Due to the risk of developing hepatic toxicity (increased transaminase activity, liver failure, fulminant hepatitis), liver function should be carefully monitored when using the drug.

    In patients with liver disease, liver function status should be monitored during the period of Tienam® use. Correction of the dose is not required.

    central nervous system

    As with the use of other beta-lactam antibiotics, there have been reports of adverse reactions from the central nervous system (CNS): myoclonia, confusion and convulsions, especially when doses recommended for renal function and weight were exceeded body. Usually, similar phenomena were observed in patients with CNS lesions (brain trauma or seizures in the anamnesis) and / or in patients with impaired renal function, in whom cumulation of the drug is possible. In this regard, especially in such patients, it is extremely necessary to adhere strictly to the recommended doses (see the section "Method of administration and dose"). In patients with convulsive disorders, anticonvulsant therapy should be continued.

    If there is tremor, myoclonia or seizures, patients should be referred for a neurological examination and an anticonvulsant therapy should it be initiated, if it has not already been started.If symptoms from the CNS persist, then reduce the dose of Tienam® or cancel the drug.

    Tienam® should not be taken to patients with creatinine clearance ≤5 ml / min / 1.73 m2 With the exception of cases where hemodialysis will be performed no later than 48 hours after the infusion of Tienam®. The use of Tienam® in patients undergoing hemodialysis is recommended only when the benefits of treatment exceed the potential risk of seizures.

    Use in children

    In children older than 3 months, the drug is used for the same indications as in adult patients.

    Data on the efficacy and safety of Tienam® for IV administration in children up to 3 months and with impaired renal function (serum creatinine> 2 mg / dl) is not enough.

    Effect on the ability to drive transp. cf. and fur:

    Some of the undesirable reactions observed with the use of the drug may affect the ability to drive vehicles and work with mechanisms (see section "Side effect").

    Form release / dosage:

    Powder for solution for infusion, 500 mg + 500 mg.

    Packaging:

    For bottles with a capacity of 115 ml

    500 mg of imipenem, 500 mg of cilastatin sodium and 20 mg of sodium bicarbonate in a glass bottle of type III or type I according to Ev. F., sealed with a rubber stopper (according to Ev.F.) and crimped with an aluminum cap and plastic cap "flip-off ". The label of the primary package has an elongation with a slot (for ease of use of the vial when infusions are introduced). 5 bottles per box cardboard complete with an equal number of connecting tubes and instructions for use.

    For bottles with a capacity of 20 ml

    500 mg of imipenem, 500 mg of cilastatin sodium and 20 mg of sodium bicarbonate in a glass bottle of type I according to EF, sealed with a rubber stopper (according to Ev.F.) and crimped with an aluminum cap and a plastic flip-off cap. For 10 bottles with instructions for use in plastic pallet wrapped with foil or 25 bottles in a plastic tray with instructions for use in a cardboard box.

    Storage conditions:

    Store at a temperature not exceeding 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after expiry date.

    Terms of leave from pharmacies:On prescription
    Registration number:П N014066 / 02
    Date of registration:31.03.2008
    The owner of the registration certificate:Merck Sharp and Doum B.V.Merck Sharp and Doum B.V. Netherlands
    Manufacturer: & nbsp
    Representation: & nbspMSD Pharmaceuticals Ltd.MSD Pharmaceuticals Ltd.
    Information update date: & nbsp11.10.2015
    Illustrated instructions
      Instructions
      Up